FY2026 EPS Estimates for ADMA Biologics Lifted by Analyst

ADMA Biologics Inc (NASDAQ:ADMA) – Investment analysts at Cantor Fitzgerald boosted their FY2026 earnings per share estimates for ADMA Biologics in a research report issued to clients and investors on Thursday, November 6th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of $0.82 for the year, up from their prior forecast of $0.80. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. During the same period in the prior year, the firm posted $0.15 EPS. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS.

Separately, Weiss Ratings cut shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, ADMA Biologics presently has a consensus rating of “Buy” and an average price target of $28.50.

ADMA Biologics Price Performance

ADMA stock opened at $16.03 on Monday. The business has a 50 day moving average price of $15.30 and a 200 day moving average price of $17.74. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of 18.64 and a beta of 0.40. ADMA Biologics has a fifty-two week low of $13.50 and a fifty-two week high of $25.67.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank boosted its stake in ADMA Biologics by 0.8% during the 2nd quarter. Amalgamated Bank now owns 67,665 shares of the biotechnology company’s stock worth $1,232,000 after purchasing an additional 540 shares during the period. New York State Teachers Retirement System lifted its holdings in ADMA Biologics by 0.3% in the second quarter. New York State Teachers Retirement System now owns 222,461 shares of the biotechnology company’s stock valued at $4,051,000 after acquiring an additional 571 shares during the period. Quadrant Capital Group LLC boosted its holdings in ADMA Biologics by 3.9% during the second quarter. Quadrant Capital Group LLC now owns 16,660 shares of the biotechnology company’s stock worth $303,000 after buying an additional 629 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of ADMA Biologics by 1.3% during the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company’s stock worth $1,002,000 after acquiring an additional 670 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in ADMA Biologics by 28.9% during the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 700 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.